Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial.
D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34 / Q000378:metabolism; D019496:Cancer Vaccines / Q000276:immunology*; D002985:Clinical Protocols; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D018014:Gene Transfer Techniques; D005822:Genetic Vectors; D006801:Humans; D007114:Immunization; D008297:Male; D008545:Melanoma / Q000276:immunology*; D014442:Monophenol Monooxygenase / Q000235:genetics*; D014161:Transduction, Genetic; D014616:Vaccinia virus / Q000276:immunology
D018952:Antigens, CD34; D019496:Cancer Vaccines; D014442:Monophenol Monooxygenase